Crewe Advisors LLC Makes New $98,000 Investment in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Crewe Advisors LLC acquired a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,075 shares of the company’s stock, valued at approximately $98,000.

Other institutional investors have also added to or reduced their stakes in the company. BNP Paribas purchased a new stake in shares of GE HealthCare Technologies during the 1st quarter valued at approximately $30,000. Rise Advisors LLC lifted its stake in shares of GE HealthCare Technologies by 241.4% during the 1st quarter. Rise Advisors LLC now owns 338 shares of the company’s stock valued at $31,000 after buying an additional 239 shares in the last quarter. Riverview Trust Co purchased a new stake in shares of GE HealthCare Technologies during the 1st quarter valued at approximately $31,000. Annapolis Financial Services LLC lifted its stake in shares of GE HealthCare Technologies by 171.9% during the 1st quarter. Annapolis Financial Services LLC now owns 348 shares of the company’s stock valued at $32,000 after buying an additional 220 shares in the last quarter. Finally, Turtle Creek Wealth Advisors LLC purchased a new stake in shares of GE HealthCare Technologies during the 4th quarter valued at approximately $30,000. 82.06% of the stock is owned by institutional investors.

Insider Activity at GE HealthCare Technologies

In other GE HealthCare Technologies news, insider Frank R. Jimenez purchased 1,315 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was bought at an average cost of $76.52 per share, with a total value of $100,623.80. Following the transaction, the insider now directly owns 75,796 shares in the company, valued at approximately $5,799,909.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Frank R. Jimenez acquired 1,315 shares of GE HealthCare Technologies stock in a transaction on Wednesday, May 1st. The stock was acquired at an average cost of $76.52 per share, for a total transaction of $100,623.80. Following the purchase, the insider now owns 75,796 shares in the company, valued at $5,799,909.92. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Taha Kass-Hout sold 3,300 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total transaction of $259,710.00. Following the sale, the chief technology officer now owns 67,300 shares of the company’s stock, valued at $5,296,510. The disclosure for this sale can be found here. Insiders sold a total of 90,482 shares of company stock valued at $7,369,137 in the last three months. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GEHC has been the topic of a number of analyst reports. Bank of America decreased their target price on shares of GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. Evercore ISI upped their target price on shares of GE HealthCare Technologies from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Mizuho decreased their target price on shares of GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Argus upped their target price on shares of GE HealthCare Technologies from $80.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Finally, Citigroup upped their target price on shares of GE HealthCare Technologies from $88.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, GE HealthCare Technologies has an average rating of “Moderate Buy” and a consensus price target of $94.09.

GE HealthCare Technologies Trading Up 1.1 %

GEHC traded up $0.88 during trading on Friday, hitting $80.80. 361,206 shares of the stock traded hands, compared to its average volume of 3,074,088. The firm has a market capitalization of $36.88 billion, a P/E ratio of 23.37, a price-to-earnings-growth ratio of 2.87 and a beta of 1.20. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.06 and a quick ratio of 0.83. The firm has a 50-day moving average of $78.68 and a 200 day moving average of $82.12. GE HealthCare Technologies Inc. has a 12-month low of $62.35 and a 12-month high of $94.50.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Tuesday, April 30th. The company reported $0.90 EPS for the quarter, hitting the consensus estimate of $0.90. GE HealthCare Technologies had a net margin of 8.05% and a return on equity of 25.32%. The firm had revenue of $4.65 billion during the quarter, compared to analysts’ expectations of $4.80 billion. During the same period last year, the company posted $0.85 EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. Equities research analysts anticipate that GE HealthCare Technologies Inc. will post 4.27 EPS for the current year.

GE HealthCare Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Friday, July 19th will be given a dividend of $0.03 per share. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.12 dividend on an annualized basis and a yield of 0.15%. GE HealthCare Technologies’s dividend payout ratio (DPR) is currently 3.51%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.